Company Overview - Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines for central nervous system (CNS) disorders [3] - The company utilizes a unique RAP technology platform based on pioneering discoveries related to receptor associated proteins (RAPs) in the brain, allowing for a differentiated approach in drug discovery [3] - The precision neuroscience pipeline includes the lead clinical program RAP-219, which targets specific RAPs in discrete brain regions and is currently in trials for focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania [3] Upcoming Events - Management will present at the TD Cowen 45 Annual Health Care Conference in Boston on March 4, 2025, from 3:10 to 3:40 PM EST [1] - The company will also participate in the Stifel 2025 Virtual CNS Forum on March 19, 2025, from 10:30 to 10:55 AM EST [2] - Live and archived webcasts of these presentations will be available on the company's website under the "Investors" section [2]
Rapport Therapeutics to Participate in Upcoming Investor Conferences